BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31179242)

  • 1. A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma.
    Kim SH; Park WS; Park B; Pak S; Chung J
    Front Oncol; 2019; 9():413. PubMed ID: 31179242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy.
    Kim SH; Kim JK; Park EY; Joo J; Lee KH; Seo HK; Joung JY; Chung J
    PLoS One; 2019; 14(2):e0211105. PubMed ID: 30785902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
    Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
    Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma.
    You D; Lee C; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2016 Nov; 142(11):2331-8. PubMed ID: 27553579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study.
    Kim SH; Lee DE; Joung JY; Seo HK; Lee KH; Chung J
    Investig Clin Urol; 2020 Mar; 61(2):146-157. PubMed ID: 32158965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry.
    Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
    Cancer Med; 2019 Jul; 8(7):3401-3410. PubMed ID: 31070307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Hsieh PY; Hung SC; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Cheng CL; Chiu KY
    Urol Oncol; 2021 Jul; 39(7):422-430. PubMed ID: 33934963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative apolipoprotein B/A1 ratio is an independent prognostic factor in metastatic renal cell carcinoma.
    Zhang F; Xie Y; Ma X; Gu L; Li H; Li X; Guo G; Zhang X
    Urol Oncol; 2019 Mar; 37(3):184.e9-184.e17. PubMed ID: 30509867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study.
    Xu WH; Wang J; Huo DZ; Yin GC; Cao DL; Shi GH; Qu YY; Ye DW; Zhang HL
    Med Sci Monit; 2019 Nov; 25():8984-8994. PubMed ID: 31769434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b).
    Stellato M; Santini D; Verzoni E; De Giorgi U; Pantano F; Casadei C; Fornarini G; Maruzzo M; Sbrana A; Di Lorenzo G; Soraru M; Naglieri E; Buti S; De Vivo R; Napolitano A; Vignani F; Mucciarini C; Grillone F; Roviello G; Di Napoli M; Procopio G
    Front Oncol; 2021; 11():682449. PubMed ID: 34168997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines.
    Gil L; Alves FR; Silva D; Fernandes I; Fontes-Sousa M; Alves M; Papoila A; Da Luz R
    Cureus; 2022 Feb; 14(2):e22224. PubMed ID: 35340486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma.
    Furubayashi N; Negishi T; Yamashita T; Kusano S; Taguchi K; Shimokawa M; Nakamura M
    Mol Clin Oncol; 2017 Sep; 7(3):454-460. PubMed ID: 28781819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis.
    Maisel F; Smolle MA; Mollnar S; Riedl JM; Barth DA; Seles M; Terbuch A; Rossmann CH; Eisner F; Mannweiler S; Hutterer G; Zigeuner R; Pummer K; Smolle-Jüttner FM; Lindenmann J; Stotz M; Gerger A; Jost PJ; Bauernhofer T; Pichler M; Posch F
    Clin Genitourin Cancer; 2022 Aug; 20(4):344-353. PubMed ID: 35443915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic renal cell carcinoma to the pancreas: Clinical features and treatment outcome.
    Shin TJ; Song C; Jeong CW; Kwak C; Seo S; Kang M; Chung J; Hong SH; Hwang EC; Park JY; Lee H
    J Surg Oncol; 2021 Jan; 123(1):204-213. PubMed ID: 33047324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry.
    Meagher MF; Mir MC; Autorino R; Minervini A; Kriegmair M; Maurer T; Porpiglia F; Van Bruwaene S; Linares E; Hevia V; Musquera M; Roussel E; Pavan N; Antonelli A; Zhang S; Ghali F; Patel D; Javier-Desloges J; Bradshaw A; Rubio J; Guruli G; Tracey A; Campi R; Albersen M; Furlan M; McKay RR; Derweesh IH
    Clin Genitourin Cancer; 2022 Aug; 20(4):326-333. PubMed ID: 35585014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy.
    Kim SH; Suh YS; Lee DE; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
    Oncotarget; 2017 Nov; 8(55):93633-93643. PubMed ID: 29212178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
    Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.